Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG versus lactulose for hepatic encephalopathy
IRCT20250903067114N1Phase 2Completed
- Sponsor
- Bushehr University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatic encephalopathy (HE) comparing Lactulose group with PEG group (2 arms). Primary endpoints: Severity of hepatic encephalopathy, In-hospital mortality and 3 more. Started Oct 2025; status: completed.
02
Drugs
macrogollactulose
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on IRCT20250903067114N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250903067114N1.